Trial Profile
A Phase II, Double-blind, Parallel Group, Dose-selection Study to Compare Antifibrinolytic MDCO-2010 vs. Placebo and Tranexamic Acid in Reducing Blood Loss in Patients Undergoing Primary Cardiac Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MDCO 2010 (Primary) ; Tranexamic acid
- Indications Surgical blood loss
- Focus Therapeutic Use
- Sponsors The Medicines Company
- 09 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Oct 2014 New trial record